Monday, September 09, 2019 1:25:19 AM
Hmmmm...remember alphapuppy’s post about a middle-age man he saw and met at June’s ASCO, and had a small talk... not an oncologist and is from Philadelphia could it be Michael McNally? Who is Merck’s President of Global Vaccines and his Linkedln shows Greater Philadelphia area.....................
Thanks for your sleuthing.
I did notice like everyone else Alphapuppy’s remarks!
It did peaked my interest back then: clearly highly unusual and suggestive!
At the time was too VAGUE: As the Philly area and a 80 mile radius encompasses a wide swath of Drug Co’s where when I was working there are many all day Drug co presentations analyst/money manager
Have you sent a reply to Alphapuppy or even Photonic5 both of which could comment re the photo
Michael McNally.
Pending both commentary these are elaborate investigative documented meetings that finally get up the corporate ladder for R&D head Perlmutter to go thru the Pro’s/Con’s vis a vis their corporate strategy: armies of highly skilled professionals from various key depts chime in re Merger/Acquisitions done in secrecy.
Hard to value! without Top Line
BUT with Top Line: PRICE is HIGHER!
Best to do a Partnership deal: $ Upfront on a trial + Earn Out with various milestones ala Roche deals
To do a buyout before Top Line that would satisfy CEO Linda Powers?
AND
The other side of it: have to justify valuation to their Bd of Dir; Institutional shareholders
appears to me to be A STRETCH!
Way too speculative.
Seriously one has to remind themselves of the City Trust? London CEO Linda Powers interview:
“What does Big Pharma have to offer except money ....
GO BIG or GO HOME!
Or the hire of Dr. Kevin Duffy is her inscrutable way of indicating we aren’t hamstrung as we have the talent to
Do a lot of it ourselves!
So there are OODLES of MASSIVE ISSUES that need to be addressed BEFORE one get’s OVER EXUBERANT.
Let’s walk versus RUN until more is known.
NWBO is “in the catbird’s seat “ although it’s priced for death by the marketplace
DIFFERENT STROKES FOR DIFFERENT FOLKS
DIFFERENT STROKES FOR DIFFERENT FOLKS
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
